Hosted on MSN5d
Dr Reddy’s and Shanghai Henlius sign agreement for HLX15
Dr Reddy's Laboratories has signed a licence agreement with Shanghai Henlius Biotech to develop and commercialise HLX15, a ...
Business Wire6d
Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe
with intravenous as well as subcutaneous formulations. HLX15 is being developed as a biosimilar of Darzalex® & Darzalex Faspro®*, which are indicated for the treatment of multiple myeloma.
Pharmabiz6d
Dr Reddy’s inks pact with Henlius to commercialize HLX1, a biosimilar candidate in US & Europe
Dr Reddy’s inks pact with Henlius to commercialize HLX1, a biosimilar candidate in US & Europe: Our Bureau, Bengaluru Thursday, February 6, 2025, 17:20 Hrs [IST] Dr Reddy’s La ...
PharmiWeb22d
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024
COPENHAGEN, Denmark; January 22, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product ...
money.rediff6d
Dr Reddy's Subsidiary Partners with Henlius for Cancer Drug
Dr Reddy's Laboratories subsidiary signs licence agreement with Shanghai Henlius Biotech for development and ...
Dr Reddy’s arm ties up with Shanghai Henlius Biotech
New Delhi: Dr Reddy’s Laboratories on Thursday said its subsidiary has inked a licence agreement with Shanghai Henlius ...
Business Insider21d
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024
COPENHAGEN, Denmark; January 22, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product ...